MedTrace Logo

Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL

NCT04582487 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-02-07

No results posted yet for this study

Summary

This is a biological study for R/R T-ALL/LBL or ETP-ALL patients. Bone marrow and/or peripheral blood samples will be subjected to genomic, DSRP profiling and phosphoproteomic screening to identify novel potential therapeutic approach and thus, eligibility for treatment based on molecular and DSRP data. As soon as genomic and DSRP profiling are made available, local Investigator can submit to local ethic committee a request for clinical use of identified compound.

Conditions

  • T Acute Lymphoblastic Leukemia
  • Early T Acute Lymphoblastic Leukemia
  • T-lymphoblastic Lymphoma
  • Etp All

Interventions

OTHER

bone marrow and/or peripheral blood samples withdrawal

bone marrow and/or peripheral blood samples evaluation

Sponsors & Collaborators

  • Gruppo Italiano Malattie EMatologiche dell'Adulto

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-19
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04582487 on ClinicalTrials.gov